医学
免疫疗法
肺炎
肺癌
不利影响
细胞毒性T细胞
无容量
免疫系统
免疫学
肿瘤科
内科学
癌症研究
肺
生物
生物化学
体外
作者
Qin Zhang,Liansha Tang,Yaqi Zhou,Wenbo He,Weimin Liu
标识
DOI:10.3389/fimmu.2021.663986
摘要
Immunotherapy that includes programmed cell death-1 (PD-1), programmed cell death- ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors has revolutionized the therapeutic strategy in multiple malignancies. Although it has achieved significant breakthrough in advanced non-small cell lung cancer patients, immune-related adverse events (irAEs) including checkpoint inhibitor pneumonitis (CIP), are widely reported. As the particularly worrisome and potentially lethal form of irAEs, CIP should be attached more importance. Especially in non-small cell lung cancer (NSCLC) patients, the features of CIP may be more complicated on account of the overlapping respiratory signs compromised by primary tumor following immunotherapy. Herein, we included the previous relevant reports and comprehensively summarized the characteristics, diagnosis, and management of CIP. We also discussed the future direction of optimal steroid therapeutic schedule for patients with CIP in NSCLC based on the current evidence.
科研通智能强力驱动
Strongly Powered by AbleSci AI